If you've looked into GLP-1 care, you've run into both names. Semaglutide is the one behind Ozempic, Wegovy and Rybelsus. Tirzepatide is behind Mounjaro and Zepbound. They get talked about as rivals, but they're more like two tools built on the same idea, with one real difference in how they work. Here's the honest comparison.
The one real mechanistic difference
Semaglutide mimics a single gut hormone, GLP-1, which tells the pancreas to release insulin when blood sugar is up, slows how fast the stomach empties, and signals appetite centers in the brain. Tirzepatide mimics two hormones at once: GLP-1 and a second one called GIP. That dual action is the whole reason it exists, and it appears to be why, on average, it produces more weight loss.
What the trials actually show
Both have been studied in large, randomized, placebo-controlled trials — the STEP program for semaglutide and the SURMOUNT program for tirzepatide — a level of evidence well beyond most compounds discussed on this site. In those trials, semaglutide produced roughly 15% average body-weight reduction in adults with obesity, and tirzepatide roughly 20%. In 2025 a head-to-head trial compared the two directly for obesity and found tirzepatide produced greater average weight loss than semaglutide.
Side by side
- How it works — semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual GIP and GLP-1 receptor agonist.
- Average weight loss in obesity trials — semaglutide about 15%, tirzepatide about 20%, and more than semaglutide in a direct head-to-head.
- FDA approval — both are approved, for type 2 diabetes and (as Wegovy and Zepbound) for chronic weight management.
- Dosing — both are once-weekly injections, titrated up slowly to limit side effects.
- Side effects — both are mainly gastrointestinal (nausea, sometimes vomiting or constipation), most common while the dose is increasing.
So is tirzepatide just better?
More average weight loss is not the same as better for you. Tolerability varies person to person, cost and insurance differ, and a licensed provider weighs your history, other conditions, and goals before anything is prescribed. The newer medicine also has a shorter real-world track record. The honest answer is that these are two strong, approved options, and which one fits is a clinical decision, not a leaderboard.
Compounded versions of both exist, but the shortages that once justified wide compounding have been declared resolved, and that enforcement window has closed. What you actually receive — an FDA-approved product or a compounded preparation — depends on the pathway a clinic offers. Compounded medicines are not FDA-approved.
Keep reading: the graded evidence for semaglutide, the graded evidence for tirzepatide, and how GLP-1 medicines actually work.
Sources
The primary sources behind this article — so you can read them yourself.
- Semaglutide — graded evidence & primary sources — New Start MD
- Tirzepatide — graded evidence & primary sources — New Start MD
- GLP-1 agonists — patient overview — MedlinePlus
- Drugs@FDA (official labels) — U.S. Food and Drug Administration
Products are available only by prescription after a consultation with a licensed provider, who decides whether treatment is appropriate. Many compounds described here are not FDA-approved medicines and have not been tested in people for the uses described; information on this site is educational and is not medical advice.